Authors: Z. Adam 1; Z. Řehák 2; M. Krejčí 1; I. Boichuk 1; L. Pour 1 Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1; Oddělení nukleární medicíny, MOÚ Brno 2 Published in: Klin Onkol 2026; 39(1): 10-30 Category: Review
Background: Monoclonal immunoglobulin (M-Ig) and/or free light chains (FLC) can cause a wide range of organ and tissue damage. The most common are various forms of nephropathies, for which the term monoclonal gammopathy of renal significance was created, and a morphological classification was proposed by the „International Kidney and Monoclonal Gammopathy Research Group.“ Another large group consists of clinical entities where, among other things, various forms of skin damage occur. For these, the group designation monoclonal gammopathy of cutaneous significance was created. Although the etiopathogenesis is hematologic, the symptoms lead patients with this form of monoclonal gammopathy-related damage to dermatology clinics. Aim: Dermatological publications from the last 5 years distinguish diseases with a clearly expressed etiopathogenetic connection to monoclonal gammopathy, defining a total of 12, and then mention other diseases in which the etiopathogenetic relationship is less clear. The group of skin diseases with a clearly demonstrated connection to monoclonal gammopathy includes: AL amyloidosis of the skin, cutaneous macroglobulinemia, skin changes in POEMS syndrome, scleromyxedema, scleroderma, diffuse normolipidemic xanthomas, necrobiotic xanthogranuloma, urticaria in Schnitzler syndrome, telangiectasia in TEMPI syndrome, localized erythema in AESOP syndrome, cryoglobulinemic skin changes, cutis laxa (loose skin). Among the diseases with a less clear connection to monoclonal immunoglobulin, we mention IgA pemphigus. The text provides brief descriptions supplemented with imaging documentation of cases we have encountered over the past 35 years. Conclusion: If a dermatologist encounters the mentioned diseases, they should examine M-Ig and FLC, and in the case of a positive finding, consult with a hematologist regarding the possibility of targeted therapy.
free light chains – monoclonal immunoglobulin – monoclonal gammopathy of cutaneous significance
1. Cetkovská P, Pizinger K, Štork J. Kožní změny u interních onemocnění. Praha: Grada 2010.
2. Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol 2017; 31 (1): 45–52. doi: 10.1111/jdv.13847.
3. Ríos-Tamayo R, Paiva B, Lahuerta JJ et al. Monoclonal gammopathies of clinical significance: a critical appraisal. Cancers (Basel) 2022; 14 (21): 5247. doi: 10.3390/cancers14215247.
4. Claveau JS, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J 2022; 12 (4): 58. doi: 10.1038/s41408-022-00661-1.
5. Berk-Krauss J, Rosenbach M. Monoclonal gammopathy of cutaneous significance. J Am Acad Dermatol 2025; 93 (4): 1042–1048. doi: 10.1016/j.jaad.2025.05.1432.
6. Iberri D, Liedtke M. MGCS: where do we stand today? Hematology Am Soc Hematol Educ Program 2024; 2024 (1): 482–488. doi: 10.1182/hematology.2024000572.
7. Flodrová P, Pika T, Flodor P. AL amyloidóza v obrazech. Trans Hematol Dnes 2014; 20 (3): 76–80.
8. Pika T. Diagnostika a léčba systémové AL amyloidózy: doporučení vypracovaná Českou myelomovou skupinou (CMG), Myelomovou sekcí České hematologické společnosti ČLS JEP. Trans Hematol Dnes 2022; 28 (Suppl 1): 6–40.
9. Khogeer A, Dupuy A. Cutaneous macroglobulinosis with Waldenström macroglobulinemia and Bing-Neel syndrome: a case report. JAAD Case Rep 2025; 61 : 82–84. doi: 10.1016/j.jdcr.2025.04.009.
10. Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol 2023; 98 (12): 1934–1950. doi: 10.1002/ajh.27081.
11. Lee K, Kourelis T, Tschautscher M et al. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia 2025; 39 (3): 703–709. doi: 10.1038/s41375-024-02489-z.
12. Gallardo-Pérez MM, Negrete-Rodríguez P, Gertz MA et al. The Latin-American experience in POEMS syndrome: a study of the GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple). Acta Haematol 2025; 148 (3): 249–257. doi: 10.1159/000540890.
13. Talbot A, Forgeard N, Vaugeois T et al Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome. Haematologica 2025. doi: 10.3324/haematol.2025.287606.
14. Krausová A, Ježková J. Diabetologie, metabolismus, endokrinologie, výživa. 2023 [online]. Dostupné z: https: //www.tigis.cz/casopisy/pro-lekare/psychiatrie11/item/1485-dmev-2-2023.
15. Minařík J, Ščudla V, Bačovský J et al. POEMS syndrom. Onkologie 2011; 5 (3): 151–154.
16. Ueda F, Okuda M, Aburano H et al. Cranial pachymeningeal involvement in POEMS syndrome: evaluation by pre - and post-contrast FLAIR and T weighted imaging. Magn Reson Med Sci 2017; 16 (3): 231–237. doi: 10.2463/mrms.mp.2015-0014.
17. Briani C, Manara R, Lessi F et al. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy. Am J Hematol 2012; 87 (5): 539–541. doi: 10.1002/ajh.23148.
18. Ziff OJ, Hoskote C, Keddie S et al. Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. J Neurol 2019; 266 (5): 1067–1072. doi: 10.1007/s00415-019-09233-z.
19. Adam Z, Řehák Z, Keřkovský M et al. Monoclonal gammopathy of clinical significance with osteosclerotic lesions – a case report and a literature review. Klin Onkol 2024; 37 (3): 209–219. doi: 10.48095/ccko 2024209.
20. Li ZY, Chen JJ, Lu FY et al. Non-POEMS osteosclerotic multiple myeloma: clinical characteristics and differential diagnosis. J Bone Oncol 2024; 45 : 100595. doi: 10.1016/j.jbo.2024.100595.
21. Rongioletti F, Merlo G, Cinotti E et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013; 69 (1): 66–72. doi: 10.1016/j.jaad.2013.01.007.
22. Theves F, Lahuna C, Mahévas T et al. Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. J Eur Acad Dermatol Venereol 2025; 39 (5): 1011–1016. doi: 10.1111/jdv.20257.
23. Di Battista M, Grosso M, Marciano A et al. Efficacy of intravenous immunoglobulins in severe scleromyxedema dysphagia assessed by oesophageal scintigraphy. Clin Exp Rheumatol 2024; 42 (8): 1706. doi: 10.55563/clinexprheumatol/2a5goh.
24. Adam Z, Szturz P, Krejčí M et al. Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses – scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies. Vnitr Lek 2015; 61 (12): 1072–1087.
25. Knobler R, Geroldinger-Simić M, Kreuter A et al. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, part 2: scleromyxoedema and scleroedema. J Eur Acad Dermatol Venereol 2024; 38 (7): 1281–1299. doi: 10.1111/jdv.19937.
26. Král Z, Krejčí M, Pour L et al. Vzácné kožní změny asociované s monoklonální gamapatií: skleredém, skleromyxedém a IgA pemfigus – popis pěti případů a přehled léčebných možností. Trans Hematol Dnes 2020; 26 (3): 226–235.
27. Cohen YK, Elpern DJ. Diffuse normolipemic plane xanthoma associated with monoclonal gammopathy. Dermatol Pract Concept 2015; 5 (4): 65–67. doi: 10.5826/dpc.0504a16.
28. Adam Z, Szeligová L, Krejčí M et al. Diffuse plane normolipemic xanthomatosis and necrobiotic xanthogranuloma associated with monoclonal gammopathy – determining the disease stage with PET-CT and treatment experience. Two case studies and literature review. Vnitr Lek 2010; 56 (11): 1158–1168.
29. Nelson CA, Zhong CS, Hashemi DA et al. A multicenter cross-sectional study and systematic review of necrobiotic xanthogranuloma with proposed diagnostic criteria. JAMA Dermatol 2020; 156 (3): 270–279. doi: 10.1001/jamadermatol.2019.4221.
30. Bassir F, Valido K, Maciejewski KR et al. Validation of the delphi consensus diagnostic criteria for necrobiotic xanthogranuloma. JAMA Dermatol 2024; 160 (12): 1361–1362. doi: 10.1001/jamadermatol.2024.3198.
31. Gupta S, Joshi R, Chikhalkar S et al. Understanding the term „necrobiosis“. Indian Dermatol Online J 2024; 15 (3): 552–555. doi: 10.4103/idoj.idoj_674_23.
32. Adam Z, Veselý K, Motyčková I et al. Eylids with yellow granulomas and cough – periocular xanthogranuloma associated with adult-onset asthma. A case study and an overview of clinical forms of juvenile xanthogranuloma and its therapy. Vnitr Lek 2012; 58 (5): 365–377.
33. Adam Z, Řehák Z, Adamová Z et al. Slow increase of bilirubin concentration during administration of lenalidomide, bortezomid and dexamethasone for multiple myeloma (unmasking previously undiagnosed Gilbert syndrome) and disappearance of necrobiotic xanthogranuloma after complete remission of multiple myeloma. Klin Onkol 2022; 35 (4): 315–322. doi: 10.48095/ccko2022315.
34. Adam Z, Pour L, Řehák Z et al. Complete remission of necrobiotic xanthogranuloma after disappearance of monoclonal immunoglobulin induced by bortezomib, lenalidomid and dexamethasone. Vnitr Lek 2021; 67 (6): 352–356.
35. Steinhelfer L, Kühnel T, Jägle H et al. Systemic therapy of necrobiotic xanthogranuloma: a systematic review. Orphanet J Rare Dis 2022; 17 (1): 132. doi: 10.1186/s13023-022-02291-z.
36. Simon A, Asli B, Braun-Falco M et al. Schnitzler‘s syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68 (5): 562–568. doi: 10.1111/all.12129.
37. Lipsker D, Veran Y, Grunenberger F et al The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001; 80 (1): 37–44. doi: 10.1097/00005792-200101000-00004.
38. Adam Z, Šedivá A, Koukalová R et al. Schnitzlers syndrome differential diagnostics, and overview of therapeutic options and description of 5 cases treated with anakinra. Vnitr Lek 2016; 62 (9): 713–727.
39. Adam Z, Tomíška M, Řehák Z et al. Transformation of IgM-MGUS into Waldenström’s macroblobulinemia in two of six patients treated for Schnitzler’s syndrome. Vnitr Lek 2021; 67 (E–3): 15–23.
40. Adam Z, Mayer J, Pour L et al. Autoinflamatorní choroby se symptomy, které připomínají maligní krevní choroby – syndrom Schnitzlerové, Stillova choroba dospělých, SAPHO a VEXAS syndrom. Trans Hematol Dnes 2024; 30 (3): 151–168. doi: 10.48095/cctahd2024prolekare.cz13.
41. Sykes DB, O‘Connell C, Schroyens W. The TEMPI syndrome. Blood 2020; 135 (15): 1199–1203. doi: 10.1182/blood.2019004216.
42. Adam Z, Leová L, Patočková M et al. Description of TEMPI syndrome in Waldenström’s macroglobulinemia. Klin Onkol 2025; 38 (4): 283–301. doi: 10.48095/ccko 2025283.
43. Shaker N, Sangueza OP. Concomitant AESOP and POEMS syndrome in the context of osseous and cutaneous plasmacytomas: answer. Am J Dermatopathol 2023; 45 (12): 852–853. doi: 10.1097/DAD.0000000000 002561.
44. Yan W, Lv R, Xu J et al. Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review. Ann Hematol 2024; 103 (1): 339–341. doi: 10.1007/s00277-023-05465-2.
45. Lipsker D, Rondeau M, Massard G et al. The AESOP (adenopathy and extensive skin patch overlying a plasmacytoma) syndrome: report of 4 cases of a new syndrome revealing POEMS (polyneuropathy, organomegaly, endocrinopathy, onoclonal protein, and skin changes) syndrome at a curable stage. Medicine (Baltimore) 2003; 82 (1): 51–59. doi: 10.1097/00005792-200301000-00005.
46. Kušnierová P. Laboratorní diagnostika monoklonálních gamapatií. Ostravská univerzita 2022.
47. Duggal S, Kattamuri LVP, Toutoungy M et al. Exploring cryoglobulinemia‘s clinical Odyssey: a case series. EJHaem 2025; 6 (2): e70029. doi: 10.1002/jha2.70029.
48. Codes-Méndez H, Jeria S, Park HS et al. Clinical and serological profiles in cryoglobulinemia: analysis of isotypes and etiologies. J Clin Med 2024; 13 (20): 6069. doi: 10.3390/jcm13206069.
49. Sečníková Z. Kryoglobulinémie a kryofibrinogémie. Cesk Dermatovenerol 2018; 8 (3): 184–188.
50. Čermáková Z, Gottwaldová J. Kryoglobulinémie a její rizika při laboratorním vyšetřování – kazuistika. Klin Biochem Metab 2009; 17 (2): 79–80.
51. Adam Z, Zdražilová Dubská L, Pour L et al. Kryoglobulinémie z úhlu pohledu jednotlivých medicínských odborností. Trans Hematol Dnes 2024; 30 (4): 213–223. doi: 10.48095/cctahd2024prolekare.cz19.
52. Jančová E, Tesař V, Stejskalová A et al. Postižení ledvin u kryoglobulinémie. Prakt Lek 1998; 78 (3): 109–114.
53. Minařík J, Pika T, Bačovská J et al. Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem. Intern Med Praxi 2012; 14 (12): 478–480.
54. Battaglini J, Henderson J, Sanchorawala V et al. Teclistamab therapy for refractory type 1 cryoglobulinemia. Haematologica 2025; 110 (8): 1891–1893. doi: 10.3324/haematol.2025.287313.
55. Khodeir J, Ohanian P, Feghali J. Acquired cutis laxa: a clinical review. Int J Dermatol 2024; 63 (10): 1334–1356. doi: 10.1111/ijd.17338.
56. Nota NM, Westerman M. Severe cutis laxa caused by immunoglobulin M gammopathy. Br J Haematol 2022; 196 (4): 802. doi: 10.1111/bjh.17912.
57. Gillion V, Vekemans MC, Rinsant A et al. Acquired cutis laxa from heavy chain deposition disease. Kidney Int 2022; 102 (6): 1432–1433. doi: 10.1016/j.kint.2022. 08.035.
58. Jachiet M, Harel S, Saussine A et al. Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature. J Am Acad Dermatol 2018; 79 (5): 945–947. doi: 10.1016/j.jaad.2018.03.039.
59. Simionescu O, Tudorache SI. Autoimmune pemphigus: difficulties in diagnosis and the molecular mechanisms underlying the disease. Front Immunol 2025; 16 : 1481093. doi: 10.3389/fimmu.2025.1481093.
60. Adam Z, Feit J, Krejčí M et al. IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review. Vnitr Lek 2009; 55 (10): 981–990.
61. Koga H, Tsutsumi M, Teye K et al. Subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma: a case report and literature review. J Dermatol 2023; 50 (2): 234–238. doi: 10.1111/1346-81 38.16516.
62. Kridin K, Patel PM, Jones VA et al. IgA pemphigus: a systematic review. J Am Acad Dermatol 2020; 82 (6): 1386–1392. doi: 10.1016/j.jaad.2019.11.059.
63. Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program 2020; 2020 (1): 380–388.
64. Mahévas T, Arnulf B, Bouaziz J-D. et al Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood 2020; 135 (14): 1101–1110. doi: 10.1182/blood.2019002300.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
